Nano Antibodies Market Report 2026

The nano antibodies market size has grown rapidly in recent years. It will grow from $1.8 billion in 2025 to $2.1 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to advances in antibody engineering research, discovery of camelid antibody structures, early clinical validation studies, expansion of biotechnology research funding, improvements in recombinant expression systems.

The nano antibodies market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to growing demand for precision therapeutics, increasing investments in biologics development, expansion of oncology and infectious disease pipelines, advancements in molecular targeting technologies, rising interest in next-generation antibody formats. Major trends in the forecast period include increasing development of target-specific nano antibodies, rising use in diagnostic and imaging applications, growing adoption in targeted cancer therapies, expansion of recombinant production platforms, enhanced focus on multispecific antibody engineering.

The rising demand for personalized medicines is expected to propel the growth of the nano antibodies market in the coming years. Personalized medicines are treatments tailored to an individual’s genetic makeup, lifestyle, and environment to ensure the most effective therapy for each patient. This demand is increasing due to the growing prevalence of chronic and rare diseases, which require targeted, patient-specific therapies for optimal treatment outcomes. Nano antibodies support personalized medicine by offering highly specific, customizable, and targeted therapeutic solutions designed according to individual patient profiles and disease mechanisms. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, a notable increase from six approvals in 2022. Therefore, the increasing demand for personalized medicines is driving the nano antibodies market.

Companies in the nano antibodies market are focusing on developing innovative solutions such as fully multispecific therapeutics to improve disease targeting and treatment efficacy. Fully multispecific therapeutics are biologic drugs designed to bind simultaneously to two or more distinct targets, enabling more precise and effective treatment of complex conditions. For example, in February 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a China-based biopharmaceutical company, launched the Nano 100 Project to develop fully human nanobody therapeutics for over 100 targets. The initiative leverages Biocytogen’s proprietary RenNan mouse platform, which generates fully human nanobodies without the need for humanization. By combining high-throughput in vitro and in vivo screening technologies, the project accelerates target coverage and nanobody drug discovery. These nanobodies provide strong tissue penetration, stability, and engineering flexibility, making them suitable for advanced therapeutic approaches such as cell therapies, bispecific antibodies, antibody-drug conjugates (ADCs), and radionuclide antibody conjugates. The Nano 100 Project aims to streamline the development of novel therapeutics and deliver a wide range of high-affinity nanobody candidates for treating cancer, immune disorders, and neurological diseases.

In September 2024, Valerion Therapeutics LLC, a France-based biotechnology company, acquired Emglev Therapeutics for an undisclosed amount. With this acquisition, Valerion sought to strengthen its capabilities in antibody therapeutics and accelerate the expansion of its next-generation immunotherapy pipeline. Emglev Therapeutics, also based in France, specializes in single-domain antibodies (sdAbs), commonly referred to as nanobodies, supporting advanced research and therapeutic applications.

Major companies operating in the nano antibodies market are Sanofi S.A., AstraZeneca plc, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Innovent Biologics Inc., GenScript Biotech Corporation, Biocytogen Pharmaceuticals Co. Ltd., Beroni Group Limited., Cusabio Technology LLC, Harbour BioMed Co. Ltd., MoonLake Immunotherapeutics Co. Ltd., Alphamab Oncology Co. Ltd., Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Biolabs Inc., Promab Biotechnologies Inc., ExeVir Bio N.V., Isogenica Ltd., Allele Biotechnology And Pharmaceuticals Inc., Gulliver Biomed Inc., Capralogics Inc.

North America was the largest region in the nano antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nano antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nano antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the nano antibodies market by increasing costs of imported laboratory reagents, bioprocessing equipment, analytical instruments, and specialized raw materials used in research and production. Biotechnology hubs in North America and Europe are most affected due to dependence on global scientific supply chains, while Asia-Pacific faces higher costs in exporting research-grade products. These tariffs are raising development costs and extending commercialization timelines. However, they are also encouraging regional biomanufacturing, domestic reagent production, and localized innovation in antibody engineering technologies.

The nano antibodies market research report is one of a series of new reports that provides nano antibodies market statistics, including nano antibodies industry global market size, regional shares, competitors with a nano antibodies market share, detailed nano antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the nano antibodies industry. This nano antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nano antibodies, also known as single-domain antibodies or nanobodies, are small antibody fragments derived from the unique heavy-chain antibodies found in camelids. They maintain the full antigen-binding capability of conventional antibodies while being more stable, easier to produce, and capable of binding to hidden or hard-to-reach epitopes.

The main products of nano antibodies include single-domain antibodies, heavy-chain antibodies, recombinant nano antibodies, conjugated nano antibodies, and bispecific and multispecific nano antibodies. Single-domain antibodies are small, stable fragments derived from heavy-chain-only antibodies that retain complete antigen-binding function and are used for therapeutic, diagnostic, and research purposes. They are developed using technologies such as phage display, recombinant DNA technology, and molecular cloning, and originate from sources including animal-derived, recombinant, and plant-derived methods. These antibodies are applied in a broad range of areas, including in vitro disease detection, non-invasive in vivo diagnostics, tumor-targeted therapy, nervous system disorders, circulatory diseases, infectious diseases, and more. End-users include pharmaceutical companies, biotechnology firms, academic and research institutions, as well as hospitals and diagnostic laboratories.

The nano antibodies market consists of sales of nano antibody constructs, diagnostic reagents, therapeutic formulations, assay kits, and research-grade antibody products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.